Show simple item record

dc.contributor.authorMidgard, Håvard
dc.contributor.authorMalme, Kristian Braathen
dc.contributor.authorPihl, Charlotte Meinich
dc.contributor.authorBerg-Pedersen, Riikka Mari
dc.contributor.authorTanum, Lars Håkon Reiestad
dc.contributor.authorKlundby, Ingvild
dc.contributor.authorHaug, Anne
dc.contributor.authorTveter, Ida Giæver
dc.contributor.authorBjørnestad, Ronny
dc.contributor.authorOlsen, Inge Christoffer
dc.contributor.authorFinbråten, Ane-Kristine
dc.contributor.authorDalgard, Olav
dc.date.accessioned2024-02-21T12:03:35Z
dc.date.available2024-02-21T12:03:35Z
dc.date.created2024-02-15T14:40:48Z
dc.date.issued2023
dc.identifier.citationClinical Infectious Diseases. 2023, .en_US
dc.identifier.issn1058-4838
dc.identifier.urihttps://hdl.handle.net/11250/3119000
dc.description.abstractBackground. We aimed to evaluate the efficacy of opportunistic treatment of hepatitis C virus (HCV) infection among hospitalized people who inject drugs (PWID). Methods. We performed a pragmatic, stepped wedge cluster randomized trial recruiting HCV RNA positive individuals admitted for inpatient care in departments of internal medicine, addiction medicine, and psychiatry at three hospitals in Oslo, Norway. Seven departments were sequentially randomized to change from control conditions (standard of care referral to outpatient care) to intervention conditions (immediate treatment initiation). The primary outcome was treatment completion, defined as dispensing the final package of the prescribed treatment within six months after enrolment. Results. A total of 200 HCV RNA positive individuals were enrolled between 1 October 2019 and 31 December 2021 (mean age 47.4 years, 72.5% male, 60.5% injected past 3 months, 20.4% cirrhosis). Treatment completion was accomplished by 67 of 98 (68.4% [95% confidence interval {CI}: 58.2–77.4]) during intervention conditions and by 36 of 102 (35.3% [95% CI: 26.1–45.4]) during control conditions (risk difference 33.1% [95% CI: 20.0–46.2]; risk ratio 1.9 [95% CI: 1.4–2.6]). The intervention was superior in terms of treatment completion (adjusted odds ratio [aOR] 4.8 [95% CI: 1.8–12.8]; P = .002) and time to treatment initiation (adjusted hazard ratio [aHR] 4.0 [95% CI: 2.5–6.3]; P < .001). Sustained virologic response was documented in 60 of 98 (61.2% [95% CI: 50.8–70.9]) during intervention and in 66 of 102 (64.7% [95% CI: 54.6–73.9]) during control conditions. Conclusions. An opportunistic test-and-treat approach to HCV infection was superior to standard of care among hospitalized PWID. The model of care should be considered for broader implementation. Clinical Trials Registration. NCT04220645 Keywords. hepatitis C virus; people who inject drugs; model of care; pragmatic clinical trial; stepped wedge cluster randomized trial.en_US
dc.language.isoengen_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.titleOpportunistic Treatment of Hepatitis C Infection Among Hospitalized People Who Inject Drugs (OPPORTUNI-C): A Stepped Wedge Cluster Randomized Trialen_US
dc.typeJournal articleen_US
dc.typePeer revieweden_US
dc.description.versionpublishedVersionen_US
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode2
dc.identifier.doi10.1093/cid/ciad711
dc.identifier.cristin2246487
dc.source.journalClinical Infectious Diseasesen_US
dc.source.pagenumber9en_US
dc.relation.projectHelse Sør-Øst RHF: 2020011en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Navngivelse 4.0 Internasjonal
Except where otherwise noted, this item's license is described as Navngivelse 4.0 Internasjonal